# Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

> **NCT07049575** · PHASE1 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 24 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Ruxolitinib Cream

## Key facts

- **NCT ID:** NCT07049575
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2026-12-09
- **Final completion:** 2026-12-09
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07049575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07049575, "Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07049575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*